by S. Mann
Mann S. Tamsulosin as a ‘P’ medicine for Benign Prostatic Hyperplasia. SelfCare 2010;1(1):44-49
The reclassification of tamsulosin hydrochloride 0.4mg (Flomax Relief®) in the UK from prescription only medicine (POM) status to ‘P’ medicine (for sale under the supervision of a pharmacist) was announced in November 2009…
by Ahmed S, Rutter P M
Ahmed S, Rutter P M. UK Community Pharmacists Experiences on Over-the-Counter Tamsulosin. SelfCare 2011;2(6):152-159
In the UK, government policy toward self-care now supports the management of some long-term conditions. In 2004, simvastatin was switched to P access for people who have a moderate risk of coronary heart disease. This deregulation met with opposition from pharmacists due to concern over patient management and the increased workload burden envisaged around training and record keeping. In 2010, tamsulosin was reclassified for the treatment of urinary symptoms of benign prostatic hyperplasia (BPH); the first medicine since simvastatin to be marketed for a non self-limiting condition. This study aimed to explore community pharmacist’s early experiences with the supply of non-prescription tamsulosin.
